Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772945 | 0.86 | — | — | |
| SCHEMBL967158 | 0.79 | — | — | |
| SCHEMBL304640 | 0.77 | — | — | |
| SCHEMBL1678871 | 0.75 | ADH1A (0.46) | — | |
| SCHEMBL303775 | 0.75 | ADH1A (0.46) | — | |
| SCHEMBL1679240 | 0.75 | ADH1A (0.46) | — | |
| SCHEMBL3949141 | 0.73 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL3696316 | 0.73 | — | — | |
| SCHEMBL1146785 | 0.71 | NOS3 (0.31) | — | |
| SCHEMBL562536 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | claimed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | claimed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | claimed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | claimed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | claimed |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PIK3CD 1700/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | PIK3CD 1311/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | PIK3CD 2597/4885 |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885 |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885 |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885 |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | PIK3CD 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.